Thermo Fisher Scientific has acquired Clario, a leading healthcare research and technology company, for an undisclosed amount. The transaction sees Thermo Fisher Scientific buying Clario to significantly enhance its capabilities in clinical trial support and evidence generation. Clario specializes in providing comprehensive endpoint data solutions for pharmaceutical, biotech, and medical device partners, playing a critical role in drug development.
Clario generates high-quality clinical evidence through a broad suite of services, including electronic Clinical Outcome Assessment (eCOA), cardiac safety monitoring, medical imaging core lab services, precision motion tracking, and respiratory endpoint solutions. With over 50 years of experience, Clario has supported clinical trials over 26,000 times in more than 100 countries. Its scientific expertise and endpoint technologies have been instrumental in contributing to over 60% of all FDA drug approvals since 2019.
This acquisition is strategically aligned with Thermo Fisher Scientific's commitment to enabling scientific research and improving healthcare outcomes. By integrating Clario's extensive portfolio of digital endpoint solutions and operational expertise, Thermo Fisher will strengthen its position as a comprehensive partner across the entire drug development lifecycle. The move allows Thermo Fisher to offer more integrated and sophisticated solutions to its global client base, streamlining the process of collecting and analyzing crucial clinical trial data.
The combined entity is expected to realize significant synergies by merging Clario's specialized evidence generation platform with Thermo Fisher's broad scientific services and global reach. This integration aims to accelerate innovation in clinical research, enhance data quality, and improve efficiency for clinical trial sponsors. Ultimately, the acquisition positions the expanded Thermo Fisher Scientific to better support the development and delivery of new therapies and medical devices worldwide.